Search

News Socio-economic Benefits of Using Obinutuzumab in 1st Line Treatment of Follicular Lymphoma

Pharmacoeconomic analyses remind us that our patients' diseases affect not only themselves or the healthcare system, but also have an impact on the entire society. Patients with follicular lymphoma (FL) are also life partners, parents, relatives, and household members, and last but not least, they are also employees or service workers. How treatment success can reflect in these aspects is suggested by a German study.

Source: Non-Hodgkin Lymphomas and CLL 14. 11. 2020

News Recommended and Not Recommended Physical Activity for Individuals with Hemophilia

Physical activity is now considered a fundamental prerequisite for maintaining the health of individuals with hemophilia. The World Federation of Hemophilia (WFH) also recommends it to improve fitness and neuromuscular health. Numerous studies have shown that physical activity can help enhance the effectiveness of hemophilia treatment and prevent bleeding episodes. In older individuals, including those with hemophilia, a lack of physical activity increases the risk of developing diabetes, hypertension, dyslipidemia, obesity, and osteoporosis, along with subsequent fractures and complications associated with hemophilia.

Source: Hemophilia with Movement 25. 2. 2021

News Effect of Etanercept on Structural Changes in the Sacroiliac Joint in Patients with Early Axial Spondyloarthritis

Currently, there is limited evidence regarding the effect of tumor necrosis factor inhibitors on structural lesions in patients with early forms of axial spondyloarthritis (AxSpA). The aim of the study presented below, published in January 2021, was to evaluate structural changes in the sacroiliac joint (SIJ) on magnetic resonance imaging (MRI) after 2 years of treatment with etanercept within the clinical study EMBARK in patients with early AxSpA compared to a control cohort not treated with biologics (DESIR) and to assess the relationship between MRI changes and disease activity according to ASDAS.

Source: Arthritis 14. 8. 2021

News Long-term results of alpha-1-antitrypsin deficiency treatment –⁠ RAPID program

RAPID/RAPID Extension is the largest clinical program to date that has confirmed the benefit of alpha-1-antitrypsin inhibitor in the treatment of chronic obstructive pulmonary disease (COPD) associated with its deficiency.

Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020

News Sport and Physical Activity Benefit Hemophiliacs

Sport and physical activity are beneficial for individuals with hemophilia. This statement was confirmed by a study conducted by German and British authors published in the journal Haemophilia.

Source: Hemophilia 5. 5. 2021

News Genetic Testing in Non-Small Cell Lung Cancer -⁠ Clinical Practice Experience

Targeted therapy has brought significant improvements to certain groups of patients with non-small cell lung cancer (NSCLC). Selecting patients who will benefit from targeted therapy can be performed using molecular profiling with next-generation sequencing (NGS) techniques. However, we still lack sufficient data on the feasibility and results of such profiling in real-world clinical practice, which was the focus of an analysis recently published in The Oncologist.

Source: Genetic Profile and Treatment of NSCLC 30. 9. 2020

News Comparison of the effects of fibrinogen concentrates and fresh frozen plasma in patients with acute traumatic coagulopathy

A quasi-experimental study compared the effectiveness of fibrinogen concentrates and fresh frozen plasma in patients with severe blunt trauma requiring the administration of erythrocyte replacements.

Source: Life-threatening Bleeding 15. 6. 2022

News Manual Fascial Therapy in Patients with Hemophilic Arthropathy

Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.

Source: Hemophilia with Movement 22. 4. 2021

News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A

Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.

Source: Hemophilia 15. 9. 2021

News Digital Technology in COPD Therapy: Current Options and Future Prospects

This year, digital technologies have demonstrated their advantages in interpersonal communication, administrative processes, and in the field of medicine. The global crisis triggered by the coronavirus pandemic revealed the need to implement telemedicine into everyday medical practice. What are its options and future prospects in the therapy of patients with chronic obstructive pulmonary disease? These questions are thoroughly addressed in an article published in the Journal of Thoracic Disease last fall.

Source: Treatment of Asthma and COPD 1. 9. 2020

News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis

Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.

Source: Biological Treatment 26. 10. 2020

News Webinar SGLT2i in ESC HF Guidelines vs. Real Practice

Dear Doctor, Boehringer Ingelheim, in collaboration with the 2nd Department of Internal Medicine -⁠ Department of Cardiology and Angiology, General University Hospital and 1st Faculty of Medicine, Charles University, cordially invites you to an online discussion to be held on Tuesday, November 23, 2021, from 5 : 00 PM to 6 : 30 PM. More information can be found in the attached invitation below.

Source: Heart Failure 18. 11. 2021

News Quality of Life in Patients with mCRC Treated with mFOLFOXIRI and Panitumumab

At the congress of the European Society for Medical Oncology (ESMO) in September 2019, the results of the VOLFI study were presented, which also monitored the quality of life in patients with primarily unresectable wild-type (wt-RAS) metastatic colorectal cancer (mCRC) with an ECOG performance status of 0–1.

Source: Colorectal Cancer 16. 6. 2020

News Current Status in the Issue of Alpha-1-Antitrypsin Deficiency

Material by Italian and Swiss authors published in the European Respiratory Review details current insights into alpha-1-antitrypsin (AAT) deficiency and the possibilities for its diagnosis and treatment. We provide a summary of the main points, including the specific option of augmentation therapy with exogenous AAT.

Source: Deficiency of Alpha-1-Antitrypsin 12. 1. 2022

News Association Between Sartan Therapy and Lower Incidence of Epilepsy in Hypertensive Patients?

Arterial hypertension (AH) is one of the non-cerebral comorbidities of epilepsy, with the renin-angiotensin system possibly being the central mediator of the connection between these diseases. The German study cited below therefore examined whether therapy with AT1 receptor blockers for angiotensin II (ARBs, i.e., sartans) reduces the risk of epilepsy in patients with AH as suggested by animal studies.

Source: Sartans in the Treatment of Hypertension 25. 5. 2023